
1. malar j. 2015 apr 16;14:164. doi: 10.1186/s12936-015-0625-3.

polymorphisms chloroquine resistance-associated genes plasmodium vivax in
ethiopia.

golassa l(1)(2), erko b(3), baliraine fn(4), aseffa a(5), swedberg g(6).

author information: 
(1)aklilu lemma institute pathobiology, addis ababa university, addis ababa,
ethiopia. lgolassa@gmail.com.
(2)armauer hansen research institute, addis ababa, ethiopia. lgolassa@gmail.com.
(3)aklilu lemma institute pathobiology, addis ababa university, addis ababa,
ethiopia.
(4)department biology, letourneau university, longview, tx, usa.
(5)armauer hansen research institute, addis ababa, ethiopia.
(6)department medical biochemistry microbiology, uppsala university,
uppsala, sweden.

erratum in
    malar j. 2018 may 2;17 (1):188.

background: evidence decreasing chloroquine (cq) efficacy plasmodium 
vivax reported many endemic countries world. ethiopia, p.
vivax accounts 40% malaria cases cq first-line drug for
vivax malaria. mutations multidrug resistance 1 (pvmdr-1) k10 insertion in
the pvcrt-o genes identified possible molecular markers of
cq-resistance (cqr) p. vivax. despite reports cq treatment failures, no
data currently available prevalence molecular markers p. vivax
resistance ethiopia. objective study determine the
prevalence mutations pvmdr-1 k10 insertion pvcrt-o genes.
methods: total 36 p. vivax clinical isolates collected west arsi
district ethiopia. sequencing used analyse polymorphisms pvcrt-o
and pvmdr-1 genes.
results: sequencing results pvmdr-1 fragment showed presence two
non-synonymous mutations positions 976 1076. y → f change codon 976
(tac → ttc) observed 21 (75%) 28 isolates f → l change
(at codon 1076), due single mutation (ttt → ctt), observed 
100% isolates. 33 samples successfully amplified pvcrt-o, the
majority isolates (93.9%) wild type, without k10 insertion.
conclusions: high prevalence mutations candidate genes conferring cqr p.
vivax identified. fact cq still first-line treatment for
vivax malaria, significance mutations pvcrt-o pvmdr-1 genes and
the clinical response patients' cq treatment whether thus an
association exists point mutations candidate genes cqr
requires research ethiopia.

doi: 10.1186/s12936-015-0625-3 
pmcid: pmc4404130
pmid: 25889237  [indexed medline]

